-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
2 views
SRPT stock now trades at book for the first time ever, despite historically commanding 7x–10x multiples. ELEVIDYS remains FDA-approved for ambulant use and may regain broader access with new protocols underway. Sarepta has $850M in cash, $500M+ in quarterly revenue, and is cutting $400M in costs by 2026.
